PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA IN THE MAGNIFY PHASE 3B INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE

Autor: M Coleman, DJ Andorsky, A Yacoub, JM Melear, SR Fanning, KS Kolibaba, F Lansigan, C Reynolds, G Nowakowski, M Gharibo, E Ahn, J Li, MJ Rummel, JP Sharman

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S98- (2021)

Objectives: Relapse is expected when treating patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL), with a shortened response associated with each relapse. Lenalidomide combined with rituximab (R2) has shown enhanced activity, with

Externí odkaz: https://doaj.org/article/c4a2564782f24e20971aeb2d2c6d05d0

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Autor: Nassiri F; Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada.; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Patil V; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Yefet LS; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Singh O; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Liu J; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Dang RMA; Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA., Yamaguchi TN; Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA., Daras M; Division of Neuro-oncology, University of California San Francisco, San Francisco, CA, USA., Cloughesy TF; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Colman H; Huntsman Cancer Institute and Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA., Kumthekar PU; Department of Neurology, Division of Neuro-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Chen CC; Department of Neurosurgery, University of Minnesota, Minneapolis, MI, USA., Aiken R; Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA., Groves MD; Department of Neurology, Texas Oncology, Austin, TX, USA., Ong SS; Division of Neuro-Oncology, Department of Neurology, the Ohio State University Wexner Medical Center, Columbus, Ohio, USA., Ramakrishna R; Department of Neurological Surgery, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA., Vogelbaum MA; Department of Neuro-Oncology, Neuro-Oncology Program, Moffitt Cancer Center, Tampa, FL, USA., Khagi S; Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Kaley T; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Melear JM; Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, USA., Peereboom DM; The Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA., Rodriguez A; Department of Neurosurgery, University of Arkansas for Medical Sciences, Little Rock, AK, USA., Yankelevich M; Department of Pediatrics, University of Michigan, Ann Arbor Beaumont Children's Hospital, Royal Oak, MI, USA., Nair SG; Lehigh Valley Topper Cancer Institute, Allentown, PA, USA., Puduvalli VK; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Aldape K; Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA., Gao A; Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto, Ontario, Canada., López-Janeiro Á; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain., de Andrea CE; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research (IdISNA), Pamplona, Spain., Alonso MM; Navarra Institute for Health Research (IdISNA), Pamplona, Spain.; Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.; Program of Solid Tumors, Center for the Applied Medical Research (CIMA), Pamplona, Spain., Boutros P; Department of Human Genetics, University of California Los Angeles, Los Angeles, CA, USA., Robbins J; DNATrix Inc., Carlsbad, CA, USA., Mason WP; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Sonabend AM; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Stupp R; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Fueyo J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gomez-Manzano C; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lang FF; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zadeh G; Division of Neurosurgery, University of Toronto, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.; Department of Surgery, University of Toronto, Toronto, Ontario, Canada. gelareh.zadeh@uhn.ca.

Publikováno v: Nature medicine [Nat Med] 2023 Jun; Vol. 29 (6), pp. 1370-1378. Date of Electronic Publication: 2023 May 15.

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.

Autor: Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA., Smith SD; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Roschewski MJ; National Cancer Institute, Bethesda, MD, USA., O'Brien SM; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USA., Sharman JP; Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA., Melear JM; Texas Oncology, Austin, TX, USA., Patel P; AstraZeneca, South San Francisco, CA, USA., Calvo R; AstraZeneca, Gaithersburg, MD, USA., Yang H; AstraZeneca, South San Francisco, CA, USA., Spurgeon SE; Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1728-1732. Date of Electronic Publication: 2022 Feb 24.

Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders.

Autor: Melear JM; Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA., Goldstein RM, Levy MF, Molmenti EP, Cooper B, Netto GJ, Klintmalm GB, Stone MJ

Publikováno v: Transplantation [Transplantation] 2002 Oct 27; Vol. 74 (8), pp. 1090-5.